Get started
Author

Martin Bigonnet

Observed names: Bigonnet Martin, M. Bigonnet, Martin BIGONNET
ORCID: 0000-0001-5652-3132
Observed ORCID: 0000-0001-5652-3132
OpenAlex ID: A5045355441
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
2018 · Gwen Lomberk, Yuna Blum, et al. · Nature Communications · 261
PDF
Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
2017 · Rémy Nicolle, Yuna Blum, et al. · Cell Reports · 199
PDF
Basal‐like and classical cells coexist in pancreatic cancer revealed by single‐cell analysis on biopsy‐derived pancreatic cancer organoids from the classical subtype
2020 · Natalia Juiz, Abdessamad Elkaoutari, et al. · The FASEB Journal · 148
PDF
Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer
2022 · Jérémy Guillot, Chloé Dominici, et al. · Nature Communications · 105
PDF
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
2020 · Rémy Nicolle, Yuna Blum, et al. · EBioMedicine · 93
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
2020 · R. Nicolle, O. Gayet, et al. · Annals of Oncology · 86
PDF
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
2017 · Benjamin Bian, Martin Bigonnet, et al. · EMBO Molecular Medicine · 71
PDF
A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis
2021 · Yousra Mohamed Abd-El-Halim, Abdessamad El Kaoutari, et al. · EBioMedicine · 44
PDF
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
2024 · N. Fraunhoffer, P. Hammel, et al. · Annals of Oncology · 38
PDF
Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
2019 · Benjamin Bian, Natalia Anahi Juiz, et al. · Frontiers in Oncology · 36
PDF
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
2020 · Nicolas A. Fraunhoffer, Analía Meilerman Abuelafia, et al. · Clinical Cancer Research · 35
PDF
E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
2018 · Wenjun Lan, Benjamin Bian, et al. · Scientific Reports · 34
PDF
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT
2016 · Marine Barraud, Jonathan Garnier, et al. · Oncotarget · 32
PDF
Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction
2022 · Nicolas A. Fraunhoffer, Analía Meilerman Abuelafia, et al. · npj Precision Oncology · 28
PDF
A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma
2022 · Nicolas Fraunhoffer, Brice Chanez, et al. · Gastroenterology · 25
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
2021 · R. Nicolle, O. Gayet, et al. · Translational Oncology · 16
PML hyposumoylation is responsible for the resistance of pancreatic cancer
2019 · Mirna Swayden, George Alzeeb, et al. · The FASEB Journal · 16
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
2021 · Owen Hoare, Nicolas Fraunhoffer, et al. · Cancers · 14
PDF
Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer
2024 · Nicolas Fraunhoffer, Carlos Teyssedou, et al. · Frontiers in Oncology · 12
PDF
Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers
2023 · Abdessamad El Kaoutari, Nicolas A. Fraunhoffer, et al. · EBioMedicine · 9
PDF
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
2022 · Nicolas Alejandro Fraunhoffer, Analía Meilerman Abuelafia, et al. · 癌症：英文版 · 5
PDF
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response
2021 · Nicolas A. Fraunhoffer, Analia M. Abuelafia, et al. · European Journal of Cancer · 5
Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies
2026 · Guillaume Jacquot, Marion David, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
1633P Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
2023 · N. Fraunhoffer, C. Teyssedou, et al. · Annals of Oncology · 1
PDF
Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC.
2023 · Nicolas Fraunhoffer, Carlos Teyssedou, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 58
Citation count: 1,318
H-index: 16
I10-index: 19
Year
Topic
Type